organization · Reporting owner
SCLX Stock Acquisition JV LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scilex Holding CoSCLX · Entity 7345 | 10% owner | July 03, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scilex Holding Co
Report date July 03, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 958,263 |
Reported balance
After 2026-07-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-03 · Other · Disposed 500,000 · Balance 958,263 F1: On July 3, 2026, the Reporting Person entered into a letter agreement (the "Letter Agreement") with Quantum Scan Holdings, Inc. ("Q Scan") and the other party named therein, pursuant to which the Reporting Person transferred the shares reported herein to Q Scan in exchange for shares of common stock of Q Scan. The price at which the shares reported herein are being transferred to Q Scan will be based on the closing price of the shares of Scilex common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement. F2: The number of shares beneficially owned reflects the 1-for-35 reverse stock split effected April 15, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 3, 2026, the Reporting Person entered into a letter agreement (the "Letter Agreement") with Quantum Scan Holdings, Inc. ("Q Scan") and the other party named therein, pursuant to which the Reporting Person transferred the shares reported herein to Q Scan in exchange for shares of common stock of Q Scan. The price at which the shares reported herein are being transferred to Q Scan will be based on the closing price of the shares of Scilex common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement.
F2: The number of shares beneficially owned reflects the 1-for-35 reverse stock split effected April 15, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 03, 2026 Filed Jul 8, 2026 01:25 UTC | Scilex Holding Co SCLX · Entity 7345 | OtherCommon stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-297858 · ownership.xml · nonDerivative · entry 1 SCLX Stock Acquisition JV LLC · CIK 0001994894 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 958,263 F1 · kind: On July 3, 2026, the Reporting Person entered into a letter agreement (the "Letter Agreement") with Quantum Scan Holdings, Inc. ("Q Scan") and the other party named therein, pursuant to which the Reporting Person transferred the shares reported herein to Q Scan in exchange for shares of common stock of Q Scan. The price at which the shares reported herein are being transferred to Q Scan will be based on the closing price of the shares of Scilex common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement. F1 · price: On July 3, 2026, the Reporting Person entered into a letter agreement (the "Letter Agreement") with Quantum Scan Holdings, Inc. ("Q Scan") and the other party named therein, pursuant to which the Reporting Person transferred the shares reported herein to Q Scan in exchange for shares of common stock of Q Scan. The price at which the shares reported herein are being transferred to Q Scan will be based on the closing price of the shares of Scilex common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement. F2 · balance_after: The number of shares beneficially owned reflects the 1-for-35 reverse stock split effected April 15, 2025. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 00:49 UTC | Scilex Holding Co SCLX · Entity 7345 | OtherCommon Stock | 3,250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-008463 · ownership.xml · nonDerivative · entry 1 SCLX Stock Acquisition JV LLC · CIK 0001994894 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,039,214 F1 · kind: Transferred pursuant to the terms of an Amendment to Senior Secured Promissory Note (the "Amendment Letter") the Issuer and the Reporting Person entered into with Oramed Pharmaceuticals Inc. ("Oramed") for the extension of the maturity date of that certain senior secured promissory note previously issued by the Issuer to Oramed on September 21, 2023. Under the terms of the Amendment Letter and in consideration for such extension and to limit certain noteholders' rights to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Amendment Letter)), the Reporting Person transferred to Oramed an aggregate of 3,250,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person. F1 · price: Transferred pursuant to the terms of an Amendment to Senior Secured Promissory Note (the "Amendment Letter") the Issuer and the Reporting Person entered into with Oramed Pharmaceuticals Inc. ("Oramed") for the extension of the maturity date of that certain senior secured promissory note previously issued by the Issuer to Oramed on September 21, 2023. Under the terms of the Amendment Letter and in consideration for such extension and to limit certain noteholders' rights to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Amendment Letter)), the Reporting Person transferred to Oramed an aggregate of 3,250,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 01:27 UTC | Scilex Holding Co SCLX · Entity 7345 | OtherCommon Stock | 779,371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-006876 · ownership.xml · nonDerivative · entry 1 SCLX Stock Acquisition JV LLC · CIK 0001994894 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,289,214 F1 · kind: Transferred in connection with a First Amendment to License and Commercialization Agreement (the "License Amendment") the Issuer entered into with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC ("Romeg"), as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg (the "Transfer Agreement"). In consideration of the execution of the License Amendment and the Transfer Agreement, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person. F1 · price: Transferred in connection with a First Amendment to License and Commercialization Agreement (the "License Amendment") the Issuer entered into with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC ("Romeg"), as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg (the "Transfer Agreement"). In consideration of the execution of the License Amendment and the Transfer Agreement, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:12 UTC | Scilex Holding Co SCLX · Entity 7345 | OtherCommon Stock | 5,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002437 · ownership.xml · nonDerivative · entry 1 SCLX Stock Acquisition JV LLC · CIK 0001994894 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,068,585 F1 · kind: Transferred pursuant to the terms of a Deferral and Consent Letter (collectively, the "Consent Letters") the Issuer and the Reporting Person entered into with each of (i) Nomis Bay Ltd and BPY Limited, (ii) Oramed Pharmaceuticals Inc. ("Oramed") and (iii) 3i, LP, respectively (collectively, the "Noteholders") for the deferral of certain amortization payments owned by the Issuer to the Noteholders. Under the terms of the Consent Letters and in consideration for such deferrals and to limit the Noteholders' right to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Consent Letters)), F2 · kind: (continued from footnote 1) the Reporting Person transferred to the Noteholders an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person, of which 2,500,000 shares were delivered to Oramed, 720,000 shares were delivered to BPY Limited, 1,280,000 shares were delivered to Nomis Bay Ltd, and 500,000 shares were delivered to 3i, LP. F1 · price: Transferred pursuant to the terms of a Deferral and Consent Letter (collectively, the "Consent Letters") the Issuer and the Reporting Person entered into with each of (i) Nomis Bay Ltd and BPY Limited, (ii) Oramed Pharmaceuticals Inc. ("Oramed") and (iii) 3i, LP, respectively (collectively, the "Noteholders") for the deferral of certain amortization payments owned by the Issuer to the Noteholders. Under the terms of the Consent Letters and in consideration for such deferrals and to limit the Noteholders' right to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Consent Letters)), F2 · price: (continued from footnote 1) the Reporting Person transferred to the Noteholders an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person, of which 2,500,000 shares were delivered to Oramed, 720,000 shares were delivered to BPY Limited, 1,280,000 shares were delivered to Nomis Bay Ltd, and 500,000 shares were delivered to 3i, LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.